High Tide Reports Record Q2 2026 Revenue, EBITDA, and First Positive Net Income
HITI sits 23% above its 52-week low of $2.1 on elevated volume (7.6× avg).
Summary
High Tide Inc. announced record Q2 2026 financial results, including $179.3 million in revenue and $13.9 million in Adjusted EBITDA, alongside achieving positive net income for the first time.
Key Events · Earnings and Guidance · HITI
-
Record Financial Performance
Reported record Q2 2026 revenue of $179.3 million (+30% YoY) and record Adjusted EBITDA of $13.9 million (+73% YoY), marking the fastest growth rates in 11 and 9 quarters, respectively.
-
Achieved Positive Net Income
The company generated positive net income of $0.024 million, a significant improvement from a net loss of $2.8 million in the prior year and $0.4 million sequentially.
-
Strong German Medical Cannabis Growth
Its German subsidiary, Remexian Pharma GmbH, achieved record revenue of $31.6 million and distributed a record 7.6 tonnes of medical cannabis, increasing its market share to over 14%.
-
Secured Non-Dilutive Financing
Received final credit approval for C$40 million in new senior secured credit facilities from Bank of Montreal, replacing existing facilities and supporting future growth.
Analysis · HITI · Trade & Services
High Tide Inc. delivered exceptionally strong second-quarter results, marking a significant financial turnaround with record revenue, Adjusted EBITDA, and, notably, its first positive net income. This performance is driven by robust growth in its Canadian retail operations and a substantial increase in its German medical cannabis distribution segment. The company also secured C$40 million in new senior secured credit facilities, providing non-dilutive capital for future expansion. These results indicate strong operational execution and a positive trajectory for the company's profitability and growth ambitions.
At the time of this filing, HITI was trading at $2.59 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $197.8M. The 52-week trading range was $2.10 to $4.06. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.